GeoVax Labs GOVX Stock
GeoVax Labs Price Chart
GeoVax Labs GOVX Financial and Trading Overview
| GeoVax Labs stock price | 2.03 USD |
| Previous Close | 2.06 USD |
| Open | 2.3 USD |
| Bid | 1.73 USD x 200 |
| Ask | 2.76 USD x 200 |
| Day's Range | 2.13 - 2.39 USD |
| 52 Week Range | 0.96 - 34.75 USD |
| Volume | 2.02M USD |
| Avg. Volume | 4.82M USD |
| Market Cap | 11.52M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.82 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10 USD |
GOVX Valuation Measures
| Enterprise Value | 6.8M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.5697675 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 13.510937 |
| Price/Book (mrq) | 12.6285715 |
| Enterprise Value/Revenue | 7.977 |
| Enterprise Value/EBITDA | -0.317 |
Trading Information
GeoVax Labs Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -91.58% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 34.75 USD |
| 52 Week Low | 0.96 USD |
| 50-Day Moving Average | 1.56 USD |
| 200-Day Moving Average | 7.48 USD |
GOVX Share Statistics
| Avg. Volume (3 month) | 4.82M USD |
| Avg. Daily Volume (10-Days) | 29.06M USD |
| Shares Outstanding | 5.21M |
| Float | 3.47M |
| Short Ratio | 1 |
| % Held by Insiders | 6.81% |
| % Held by Institutions | 9.84% |
| Shares Short | 470.94K |
| Short % of Float | 13.56% |
| Short % of Shares Outstanding | 13.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2523.43% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -194.58% |
| Return on Equity (ttm) | -509.28% |
Income Statement
| Revenue (ttm) | 852.28K USD |
| Revenue Per Share (ttm) | 0.64 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -17269236 USD |
| EBITDA | -21442848 USD |
| Net Income Avi to Common (ttm) | -21369040 USD |
| Diluted EPS (ttm) | -13.82 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.27M USD |
| Total Cash Per Share (mrq) | 0.37 USD |
| Total Debt (mrq) | 394.57K USD |
| Total Debt/Equity (mrq) | 79.91 USD |
| Current Ratio (mrq) | 1.061 |
| Book Value Per Share (mrq) | 0.175 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19046010 USD |
| Levered Free Cash Flow (ttm) | -11100562 USD |
Profile of GeoVax Labs
| Country | United States |
| State | GA |
| City | Smyrna |
| Address | 1955 Lake Park Drive |
| ZIP | 30080 |
| Phone | 678 384 7220 |
| Website | https://www.geovax.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Q&A For GeoVax Labs Stock
What is a current GOVX stock price?
GeoVax Labs GOVX stock price today per share is 2.03 USD.
How to purchase GeoVax Labs stock?
You can buy GOVX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GeoVax Labs?
The stock symbol or ticker of GeoVax Labs is GOVX.
Which industry does the GeoVax Labs company belong to?
The GeoVax Labs industry is Biotechnology.
How many shares does GeoVax Labs have in circulation?
The max supply of GeoVax Labs shares is 5.21M.
What is GeoVax Labs Price to Earnings Ratio (PE Ratio)?
GeoVax Labs PE Ratio is now.
What was GeoVax Labs earnings per share over the trailing 12 months (TTM)?
GeoVax Labs EPS is -13.82 USD over the trailing 12 months.
Which sector does the GeoVax Labs company belong to?
The GeoVax Labs sector is Healthcare.
GeoVax Labs GOVX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}